Symic Bio Selected for “The Best of The Liver Meeting 2018” at AASLD

SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ — Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that they were selected for “The Best of The Liver Meeting 2018” at the AASLD international liver meeting and will be presenting on its liver fibrosis program at the upcoming conference in San Francisco. Symic’s molecule, SBR-294, is unique in both its molecule class as well as in its approach to treating liver disease.  SBR-294 is a matrix-targeting glycan therapeutic that is novel to Symic’s therapeutic platform. The molecule targets the platelet-axis of fibrosis, which is emerging as a key driver ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 6

Ähnlich Nachrichten